Partner with Destina Genomics
License the revolutionary DGL-Tech™ and offer exclusive, PCR-Free biomarker assays.
The Service Lab Bottleneck
Offering nucleic acid diagnostics, especially miRNA assays, is complex, expensive, and slow. Multiple workflows for proteins and miRNAs create high operational costs, require specialized staff, and lead to long turnaround times (TAT) that frustrate clients.
Complex, Separate Workflows
Running a protein immunoassay (like Luminex) and a nucleic acid assay (like qPCR) requires different equipment, labs, and SOPs, splitting samples and doubling the work.
High Cost & Contamination Risk
PCR-based methods require expensive reagents (enzymes, polymerases) and dedicated clean-room facilities to prevent contamination, increasing overhead and risk.
Slow Turnaround Times (TAT)
RNA extraction, reverse transcription, and amplification steps take days, not hours. This is too slow for modern drug development and preclinical safety decisions.
The DGL-Tech™ Advantage
Our proprietary Dynamic Chemical Labelling (DGL-Tech™) is the "secret weapon." It is a PCR-Free chemistry that allows for the direct detection of nucleic acids (like miRNA) with the same simple workflow as a protein immunoassay.
- True Immunoassay Workflow: Unify your lab. Run miRNA and protein assays on the same platform, at the same time.
- Sample-to-Result in < 5 Hours: Eliminate extraction, reverse transcription, and amplification. Drastically cut your TAT.
- Offer Unique Assays: DGL-Tech™ is the only technology that enables true multiplexing of miRNA and Proteins from a single low-volume sample.
- Unmatched Specificity: Our chemical labelling achieves single-nucleotide specificity, eliminating the false positives common in PCR.
How We Can Partner
We are seeking strategic partners to deploy our validated technology. Stop competing on standard assays and start offering exclusive, high-value diagnostics.
Opportunity 1:
Become a Certified Service Partner
Offer our market-ready LiverAce™ (Luminex) kits to your clients. We provide certification, training, and list you as an official service provider, driving new revenue to your lab.
Best for: CROs and Service Labs on the Luminex platform.
Opportunity 2:
License DGL-Tech™ for Your Platform
Integrate our DGL-Tech™ chemistry into your proprietary assay platform (e.g., ELISA, Simoa, etc.). Create novel, high-margin PCR-Free assays that your competitors cannot replicate.
Best for: Diagnostic platform companies and large-scale assay manufacturers.
Opportunity 3:
Co-Develop Novel IVD Assays
Do you have a proprietary biomarker (miRNA or protein) and need a robust, multiplex-capable platform? Partner with us to co-develop the next generation of IVD and Companion Diagnostics (CDx).
Best for: Pharma, Biotech, and R&D institutions with novel IP.
A De-Risked, Validated Platform
DGL-Tech™ is not theoretical. It is a robust, validated chemistry already in use by global leaders in diagnostics and research services.
Validated on Luminex xMAP®, our core strength for high-performance, PCR-Free multiplexing.
Proven on high-sensitivity platforms like Quanterix Simoa®.
In operational use by leading global CROs, including MilliporeSigma (CADI Lab).
Let's Build the Future of Diagnostics. Together.
Contact our leadership team today to discuss licensing or partnership opportunities and gain a definitive competitive advantage in the biomarker market.
Schedule a Partnership Call